Research Advancement of MicroRNA on Pancreatic Cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

YAO Rucheng , ZHENG Jun , XING Rongchun

Department of General Surgery， The First Clinical Medicine College， Three Gorges University， Yichang 443000， Hubei Province， China;

Corresponding author：

Keywords：

MicroRNA; Pancreatic cancer; Tumor marker; Diagnosis; Advance

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective 　To summarize the domestic and abroad articles related to the research on the relation between microRNA （miRNA） and pancreatic cancer，and explore the important effects of miRNA expression patterns in diagnosis of pancreatic cancer.
Methods 　“microRNA and pancreatic cancer” were searched as key words by PubMed and CNKI series full-text database retrieval systems from 2000 to 2012. Totally 60 English papers and 15 Chinese papers were obtained. Choice criteria：the basic research of miRNA and pancreatic cancer，the clinical research of miRNA and pancreatic cancer， and the prospect of miRNA in pancreatic cancer diagnosis and treatment. According to the choice criteria，31 papers were finally analyzed.
Results 　The miRNA expression spectrum and specific miRNA expression such as miR-21，miR-34，miR-217，miR-196a，miR-10a，miR-155，miR-221，miR-222，miR-181a，miR-181b，miR-181d， and the family members of miR-200 and let-7 might be used as tumor markers to differentiate pancreatic cancer from normal pancreas，chronic pancreatitis or pancreatic endocrine tumors，and might be used as prognostic factor to predict the outcome.
Conclusions 　miRNA expression spectrum are not only related to diagnosis of pancreatic cancer， but also have provided a new research direction and method for gene therapy of pancreatic cancer．

Citation： YAO Rucheng,ZHENG Jun,XING Rongchun,.. Research Advancement of MicroRNA on Pancreatic Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2012, 19(8): 911-915. doi: Copy

1.	Saif MW. Pancreatic cancer：highlights from the 42nd annual meeting of the American Society of Clinical Oncology， 2006[J]. JOP， 2006， 7(4)：337-348.
2.	陈万青，张思维，郑荣寿，等. 中国肿瘤登记地区2007年肿瘤发病和死亡分析[J]. 中国肿瘤， 2011， 20(3)：162-169.
3.	Jemal A， Siegel R， Xu J， et al. Cancer statistics， 2010[J]. CA Cancer J Clin， 2010， 60(5)：277-300.
4.	Calin GA， Croce CM. MicroRNA signatures in human cancers[J]. Nat Rev Cancer， 2006， 6(11)：857-866.
5.	Thomson JM， Newman M， Parker JS， et al. Extensive post-transcriptional regulation of microRNAs and its implications for cancer[J]. Genes Dev， 2006， 20(16)：2202-2207.
6.	Zhang Y， Li M， Wang H， et al. Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis[J]. World J Surg， 2009， 33(4)：698-709.
7.	Bloomston M， Frankel WL， Petrocca F， et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis[J]. JAMA， 2007， 297(17)：1901-1908.
8.	Lee EJ， Gusev Y， Jiang J， et al. Expression profiling identifies microRNA signature in pancreatic cancer[J]. Int J Cancer， 2007， 120(5)：1046-1054.
9.	Nakata K， Ohuchida K， Mizumoto K， et al. MicroRNA-10b is overexpressed in pancreatic cancer， promotes its invasiveness， and correlates with a poor prognosis[J]. Surgery， 2011， 150(5)：916-922.
10.	Lee KH， Lotterman C， Karikari C， et al. Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer[J]. Pancreatology， 2009， 9(3)：293-301.
11.	Szafranska AE， Davison TS， John J， et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma[J]. Oncogene， 2007， 26(30)：4442-4452.
12.	Yu S， Lu Z， Liu C， et al. miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer[J]. Cancer Res， 2010， 70(14)：6015-6025.
13.	Wang J， Chen J， Chang P， et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease[J]. Cancer Prev Res (Phila)， 2009， 2(9)：807-813.
14.	Morimura R， Komatsu S， Ichikawa D， et al. Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer[J]. Br J Cancer， 2011， 105(11)：1733-1740.
15.	Liu R， Chen X， Du Y， et al. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer[J/OL]. Clin Chem， 2012， 58(3)：610-618.
16.	Habbe N， Koorstra JB， Mendell JT， et al. MicroRNA miR-155 is a biomarker of early pancreatic neoplasia[J]. Cancer Biol Ther， 2009， 8(4)：340-346.
17.	Steele CW， Oien KA， McKay CJ， et al. Clinical potential of microRNAs in pancreatic ductal adenocarcinoma [J]. Pancreas， 2011， 40(8):1165-1171.
18.	Weiss FU， Marques IJ， Woltering JM， et al. Retinoic acid receptor antagonists inhibit miR-10 a expression and block metastatic behavior of pancreatic cancer[J]. Gastroenterology， 2009， 137(6)：2136-2145.
19.	Jones S， Zhang X， Parsons DW， et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses[J]. Science， 2008， 321(5897)：1801-1806.
20.	Hruban RH， Adsay NV， Albores-Saavedra J， et al. Pancreatic intraepithelial neoplasia：a new nomenclature and classification system for pancreatic duct lesions[J]. Am J Surg Pathol， 2001， 25(5)：579-586.
21.	du Rieu MC， Torrisani J， Selves J， et al. MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions[J]. Clin Chem， 2010， 56(4)：603-612.
22.	Oh JS， Kim JJ， Byun JY， et al. Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras [J]. Int J Radiat Oncol Biol Phys， 2010， 76(1)：5-8.
23.	Ali S， Banerjee S， Logna F， et al. Inactivation of Ink4 a/Arf leads to deregulated expression of miRNAs in K-Ras transgenic mouse model of pancreatic cancer [J/OL]. J Cell Physiol， 2011 Dec 29. doi：10.1002/jcp.24036.
24.	Torrisani J， Bournet B， du Rieu MC， et al. let-7 MicroRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression[J]. Hum Gene Ther， 2009， 20(8)：831-844.
25.	Sun M， Estrov Z， Ji Y， et al. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells[J]. Mol Cancer Ther， 2008， 7(3)：464-473.
26.	Li Y， Vandenboom TG 2nd， Kong D， et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells[J]. Cancer Res， 2009， 69(16)：6704-6712.
27.	Zhang S， Cai X， Huang F， et al. Effect of trichostatin a on viability and microRNA expression in human pancreatic cancer cell line BxPC-3[J]. Exp Oncol， 2008， 30(4)：265-268.
28.	Ali S， Ahmad A， Banerjee S， et al. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF[J]. Cancer Res， 2010， 70(9)：3606-3617.
29.	Park JK， Lee EJ， Esau C， et al. Antisense inhibition of microRNA-21 or -221 arrests cell cycle， induces apoptosis， and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma[J]. Pancreas， 2009， 38(7)：e190-e199.
30.	Heyn H， Schreek S， Buurman R， et al. MicroRNA miR-548d is a superior regulator in pancreatic cancer[J/OL]. Pancreas， 2012， 41(2)：218-221.
31.	潘博，郭俊超，廖泉，等. 吉西他滨与胰腺癌化疗耐药[J]. 中国普外基础与临床杂志， 2005， 12(5)：530- 532.

1. Saif MW. Pancreatic cancer：highlights from the 42nd annual meeting of the American Society of Clinical Oncology， 2006[J]. JOP， 2006， 7(4)：337-348.
2. 陈万青，张思维，郑荣寿，等. 中国肿瘤登记地区2007年肿瘤发病和死亡分析[J]. 中国肿瘤， 2011， 20(3)：162-169.
3. Jemal A， Siegel R， Xu J， et al. Cancer statistics， 2010[J]. CA Cancer J Clin， 2010， 60(5)：277-300.
4. Calin GA， Croce CM. MicroRNA signatures in human cancers[J]. Nat Rev Cancer， 2006， 6(11)：857-866.
5. Thomson JM， Newman M， Parker JS， et al. Extensive post-transcriptional regulation of microRNAs and its implications for cancer[J]. Genes Dev， 2006， 20(16)：2202-2207.
6. Zhang Y， Li M， Wang H， et al. Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis[J]. World J Surg， 2009， 33(4)：698-709.
7. Bloomston M， Frankel WL， Petrocca F， et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis[J]. JAMA， 2007， 297(17)：1901-1908.
8. Lee EJ， Gusev Y， Jiang J， et al. Expression profiling identifies microRNA signature in pancreatic cancer[J]. Int J Cancer， 2007， 120(5)：1046-1054.
9. Nakata K， Ohuchida K， Mizumoto K， et al. MicroRNA-10b is overexpressed in pancreatic cancer， promotes its invasiveness， and correlates with a poor prognosis[J]. Surgery， 2011， 150(5)：916-922.
10. Lee KH， Lotterman C， Karikari C， et al. Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer[J]. Pancreatology， 2009， 9(3)：293-301.
11. Szafranska AE， Davison TS， John J， et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma[J]. Oncogene， 2007， 26(30)：4442-4452.
12. Yu S， Lu Z， Liu C， et al. miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer[J]. Cancer Res， 2010， 70(14)：6015-6025.
13. Wang J， Chen J， Chang P， et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease[J]. Cancer Prev Res (Phila)， 2009， 2(9)：807-813.
14. Morimura R， Komatsu S， Ichikawa D， et al. Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer[J]. Br J Cancer， 2011， 105(11)：1733-1740.
15. Liu R， Chen X， Du Y， et al. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer[J/OL]. Clin Chem， 2012， 58(3)：610-618.
16. Habbe N， Koorstra JB， Mendell JT， et al. MicroRNA miR-155 is a biomarker of early pancreatic neoplasia[J]. Cancer Biol Ther， 2009， 8(4)：340-346.
17. Steele CW， Oien KA， McKay CJ， et al. Clinical potential of microRNAs in pancreatic ductal adenocarcinoma [J]. Pancreas， 2011， 40(8):1165-1171.
18. Weiss FU， Marques IJ， Woltering JM， et al. Retinoic acid receptor antagonists inhibit miR-10 a expression and block metastatic behavior of pancreatic cancer[J]. Gastroenterology， 2009， 137(6)：2136-2145.
19. Jones S， Zhang X， Parsons DW， et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses[J]. Science， 2008， 321(5897)：1801-1806.
20. Hruban RH， Adsay NV， Albores-Saavedra J， et al. Pancreatic intraepithelial neoplasia：a new nomenclature and classification system for pancreatic duct lesions[J]. Am J Surg Pathol， 2001， 25(5)：579-586.
21. du Rieu MC， Torrisani J， Selves J， et al. MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions[J]. Clin Chem， 2010， 56(4)：603-612.
22. Oh JS， Kim JJ， Byun JY， et al. Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras [J]. Int J Radiat Oncol Biol Phys， 2010， 76(1)：5-8.
23. Ali S， Banerjee S， Logna F， et al. Inactivation of Ink4 a/Arf leads to deregulated expression of miRNAs in K-Ras transgenic mouse model of pancreatic cancer [J/OL]. J Cell Physiol， 2011 Dec 29. doi：10.1002/jcp.24036.
24. Torrisani J， Bournet B， du Rieu MC， et al. let-7 MicroRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression[J]. Hum Gene Ther， 2009， 20(8)：831-844.
25. Sun M， Estrov Z， Ji Y， et al. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells[J]. Mol Cancer Ther， 2008， 7(3)：464-473.
26. Li Y， Vandenboom TG 2nd， Kong D， et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells[J]. Cancer Res， 2009， 69(16)：6704-6712.
27. Zhang S， Cai X， Huang F， et al. Effect of trichostatin a on viability and microRNA expression in human pancreatic cancer cell line BxPC-3[J]. Exp Oncol， 2008， 30(4)：265-268.
28. Ali S， Ahmad A， Banerjee S， et al. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF[J]. Cancer Res， 2010， 70(9)：3606-3617.
29. Park JK， Lee EJ， Esau C， et al. Antisense inhibition of microRNA-21 or -221 arrests cell cycle， induces apoptosis， and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma[J]. Pancreas， 2009， 38(7)：e190-e199.
30. Heyn H， Schreek S， Buurman R， et al. MicroRNA miR-548d is a superior regulator in pancreatic cancer[J/OL]. Pancreas， 2012， 41(2)：218-221.
31. 潘博，郭俊超，廖泉，等. 吉西他滨与胰腺癌化疗耐药[J]. 中国普外基础与临床杂志， 2005， 12(5)：530- 532.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Research Advancement of MicroRNA on Pancreatic Cancer

Abstract Full text Figures/Tables Video References Cited by

Format

Content